// App-Quantinova.ai

9052 : Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

Researchers

Presenter

  • Anna Rachel Minchom

Principal Investigators

  • Nicolas Girard

  • Lyudmila Bazhenova

  • Sai-Hong Ignatius Ou

  • Shirish M. Gadgeel

  • Jos Trigo

  • Santiago Viteri

  • Daniel Backenroth

  • Archan Bhattacharya

  • Tracy Li

  • Parthiv Mahadevia

  • Joshua Bauml

Medical Centers

  • Drug Development Unit, The Royal Marsden and Institute of Cancer Research, Sutton, UK

  • Institut Curie, Paris Cedex, France

  • University of California-San Diego, San Diego, CA

  • University of California, Irvine, Fullerton, CA

  • Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI

  • Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Málaga, Spain

  • Instituto Oncológico Dr Rosell, Centro Médico Teknon, Grupo Quironsalud, Barcelona/ES

  • Janssen R&D, Raritan, NJ

  • Janssen R&D, High Wycombe, PA

  • QH, United Kingdom

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Locations

  • United Kingdom

  • France

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved